| An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three‐month randomized, placebo‐controlled, phase II study in patients with active rheumatoid arthritis … MC Genovese, A Kavanaugh, ME Weinblatt, C Peterfy, J DiCarlo, ... Arthritis & Rheumatism 63 (2), 337-345, 2011 | 250 | 2011 |
| MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA … C Peterfy, P Emery, PP Tak, M Østergaard, J DiCarlo, K Otsa, FN Sarabia, ... Annals of the rheumatic diseases 75 (1), 170-177, 2016 | 64 | 2016 |
| Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET … PG Conaghan, P Durez, RE Alten, GR Burmester, PP Tak, L Klareskog, ... Annals of the rheumatic diseases 72 (8), 1287-1294, 2013 | 63 | 2013 |
| The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy PG Conaghan, C Peterfy, E Olech, J Kaine, D Ridley, J DiCarlo, ... Annals of the Rheumatic Diseases 73 (5), 810-816, 2014 | 55 | 2014 |
| Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data AM Jarrett, DA Hormuth II, C Wu, AS Kazerouni, DA Ekrut, J Virostko, ... Neoplasia 22 (12), 820-830, 2020 | 46 | 2020 |
| Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932) CG Peterfy, E Olech, JC DiCarlo, JT Merrill, PJ Countryman, NB Gaylis Arthritis Research & Therapy 15, 1-10, 2013 | 45 | 2013 |
| Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI CG Peterfy, JC DiCarlo, E Olech, MA Bagnard, A Gabriele, N Gaylis Arthritis research & therapy 14, 1-8, 2012 | 42 | 2012 |
| Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology C Wu, G Lorenzo, DA Hormuth, EABF Lima, KP Slavkova, JC DiCarlo, ... Biophysics Reviews 3 (2), 2022 | 30 | 2022 |
| Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting JC Waterton, M Ho, LH Nordenmark, M Jenkins, J DiCarlo, G Guillard, ... European Radiology 27, 3662-3668, 2017 | 30 | 2017 |
| Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid … KD MacIsaac, R Baumgartner, J Kang, A Loboda, C Peterfy, J DiCarlo, ... PLoS One 9 (12), e113937, 2014 | 28 | 2014 |
| Quantitative magnetic resonance imaging and tumor forecasting of breast cancer patients in the community setting AM Jarrett, AS Kazerouni, C Wu, J Virostko, AG Sorace, JC DiCarlo, ... Nature protocols 16 (11), 5309-5338, 2021 | 24 | 2021 |
| Variable‐density one‐shot Fourier velocity encoding JC DiCarlo, BA Hargreaves, KS Nayak, BS Hu, JM Pauly, DG Nishimura Magnetic Resonance in Medicine: An Official Journal of the International …, 2005 | 24 | 2005 |
| Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experience CG Peterfy, P Countryman, A Gabriele, T Shaw, A Anisfeld, W Tsuji, ... The Journal of Rheumatology 38 (9), 2023-2030, 2011 | 23 | 2011 |
| Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled … C Peterfy, V Strand, L Tian, M Østergaard, Y Lu, J DiCarlo, P Countryman, ... Annals of the rheumatic diseases 76 (6), 992-997, 2017 | 22 | 2017 |
| Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis C Peterfy, GR Burmester, VP Bykerk, BG Combe, JC DiCarlo, DE Furst, ... Annals of the Rheumatic Diseases 75 (8), 1501-1505, 2016 | 22 | 2016 |
| Rituximab (RTX) plus Methotrexate (MTX) prevents bone erosion and joint-space narrowing (JSN) and reduces synovitis, osteitis as shown on MRI: Results from a randomised … C Peterfy, P Emery, PP Tak, M Østergaard, J DiCarlo, K Otsa, FN Sarabia, ... Annals of the Rheumatic Diseases 70 (3 (Suppl.)), 152, 2011 | 21 | 2011 |
| Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease … C Peterfy, P Emery, M Genovese, E Keystone, P Taylor, P Berclaz, ... | 13 | 2012 |
| Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of … C Beals, R Baumgartner, C Peterfy, A Balanescu, G Mirea, A Harabagiu, ... PLoS One 12 (12), e0187397, 2017 | 11 | 2017 |
| MRI and dose selection in a phase II trial of baricitinib with conventional synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis C Peterfy, J DiCarlo, P Emery, MC Genovese, EC Keystone, PC Taylor, ... The Journal of Rheumatology 46 (8), 887-895, 2019 | 8 | 2019 |
| SAT0492 Treatment Effects Measured by Dynamic Contrast Enhanced MRI and Ramris for Rheumatoid Arthritis C Beals, R Baumgartner, C Peterfy, A Balanescu, G Mirea, A Harabagiu, ... Annals of the rheumatic diseases 72 (Suppl 3), A748-A748, 2013 | 8 | 2013 |
Thomas YankeelovDirector, Center for Computational Oncology, The University of Texas at AustinVerified email at utexas.edu
